Fig 1: Pemafibrate inhibited IFN-γ-induced fibrotic and inflammatory markers in HPMCs. (a, b) Representative western blotting analyses showing the expression levels of (a) TGF-β and (b) secreted fibronectin from control HPMCs, and HPMCs with or without pemafibrate (40 or 60 µmol/L) after 48 h of IFN-γ stimulation. (c-h) Representative western blotting analyses showing the expression levels of (c) phospho-NF-κB and NF-κB, (d) phospho-IκBα, (e) phospho-cJun (a component of AP-1), (f) phospho-STAT1, (g) CXCL9, and (h) CXCL10 from control HPMCs, and HPMCs with or without pemafibrate (40 or 60 µmol/L) after 24 h of IFN-γ stimulation. n = 5 per group. * indicates P < 0.05 by one-way ANOVA followed by Tukey’s post-hoc test. Pema, pemafibrate.